Browsing Tag
Roche
85 posts
How petrelintide’s tolerability profile could reshape patient adherence in obesity pharmacotherapy
Can petrelintide improve adherence in obesity treatment? Discover how Zealand Pharma’s therapy could reshape the weight-loss drug market.
Can Freenome’s $1.1bn SPAC deal unlock a new chapter for blood-based multi-cancer detection?
Freenome merges with PCSC in $1.1B deal to go public as FRNM. Find out how its AI-powered blood tests could change early cancer detection.
Roche’s breast cancer pill inavolisib approved by MHRA for metastatic disease
MHRA approves inavolisib for advanced HR-positive breast cancer. Find out how Roche’s targeted therapy expands treatment options for UK patients.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A
EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.
Can Genentech’s $50 direct-to-patient Xofluza launch reshape access to flu antivirals in 2025?
Genentech slashes Xofluza price by 70% in a direct-to-patient launch with Amazon, Cost Plus, and Alto Pharmacy. See how this reshapes flu access in 2025.
Is Labcorp’s partnership with Roche the turning point for AI in cancer diagnostics?
Labcorp and Roche launch a digital pathology partnership to prepare diagnostics for AI—explore the market impact, stock sentiment, and industry risks.
Novo Nordisk seeks FDA nod for Mim8 — how will this impact hemophilia treatment and NVO stock?
Novo Nordisk files FDA application for Mim8 in hemophilia A. Learn how flexible dosing and trial data could redefine the bleeding disorder market.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.